



Available gonadorelins and their licensed indications									
Frequency	monthly	ionthly				3 monthly			6 monthly
Brand name	Zoladex	Prostap SR DCS	Decapeptyl SR	Gonapeptyl Depot	Prostap 3 DCS	Decapeptyl SR	Staladex	Zoladex LA	Decapeptyl SR
Generic Drug	Goserelin	Leuprorelin	Triptorelin	Triptorelin	Leuprorelin	Triptorelin	Leuprorelin	Goserelin	Triptorelin
Strength	3.6mg	3.75mg	3mg	3.75mg	11.25mg	11.25mg	10.72mg	10.8mg	22.5mg
Route	SC	SC	IM	SC or IM	SC	IM	SC	SC	IM
Metastatic prostate cancer	Y	Y	Y	Y	Y	Y	Y	Y	Y
Locally advanced prostate cancer, as an alternative to surgical castration	Y	Y	Y	Y	Y	Ý	Y	Y	Ý
As adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer	Y	Y	Y	N	Y	Y	Y	Y	Y
As neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer	Y	Y	Y	Ν	Y	Y	Y	Y	Y
As adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression	Y	Υ	Y	Ν	Y	Y	Y	Υ	Y
Advanced breast cancer in pre and perimenopausal women suitable for hormonal manipulation.	Y	Y	N	Ν	Y	N	N	Y	N
Alternative to chemotherapy in the standard of care for pre/perimenopausal women with oestrogen receptor (ER) positive early breast cancer.	Y	Y	N	Ν	Ν	N	N	Y (Feb 2022)	N
As adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine responsive early stage breast cancer in women at high risk of recurrence who are confirmed as pre-menopausal after completion of chemotherapy	N	N	Y	N	Y	N	N	N	N
In the management of endometriosis, alleviates symptoms, including pain, and reduces the size and number of endometrial lesions	Y	Y	Y	Y	Y	Y	N	N	N
Endometrial thinning: indicated for the prethinning of the uterine endometrium prior to endometrial ablation or resection	Y	Y	N	N	N	N	N	N	N
Uterine fibroids: In conjunction with iron therapy in the haematological improvement of anaemic patients with fibroids prior to surgery	Y	Υ	Y	Ν	Ν	N	N	Ν	N
Preoperative reduction of myoma size to reduce the symptoms of bleeding and pain in women with symptomatic uterine myomas.	N	N	N	Y	Ν	N	N	N	N
Assisted reproduction: Pituitary downregulation in preparation for superovulation.	Y	Ν	N	Ν	N	N	N	Ν	N
Precocious puberty	N	Y	N	Y	Y	Y	N	N	Y
Gender Dysphoria	N	N	N	N	N	N	N	N	Ν
Cost Indicator inclusive of all considerations	Lowest cost> Highest cost				Lowest cost> Highest cost				Lowest cost (all preps)
NB: 3 and 6 monthly administered preparations represent a cost saving over monthly administered products									

Table produced by BLMK CCG, June 2022. Ratified at June 2022 BLMK APC. Review: June 2024